The FDA's complete response letter indicates that Zynquista will not be approved at this time, which is a setback for Lexicon Pharmaceuticals. However, the company had already planned to discontinue launch preparations, which may mitigate the negative impact. The focus on the clinical development pipeline suggests a strategic pivot, but the immediate reaction is likely negative due to the regulatory setback.